54 results found.

Prostate Cancer Clinical Trial using Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Janssen Pharmaceutica N.V., Belgium - Recruiting 18 years or older.
- A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
Abiraterone Acetate; Prednisone 5 mg twice daily; Prednisone 5 mg once daily; Prednisone 2.5 mg twice daily; Dexamethasone 0.5 mg once daily

Prostate Cancer Clinical Trial using Best Systemic Therapy (BST); Best Systemic Therapy (BST) + Surgery or Radiation Therapy; Questionnaires; Phone Call/Email

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Randomized, Phase II Trial of Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer (PC).
Best Systemic Therapy (BST); Best Systemic Therapy (BST) + Surgery or Radiation Therapy; Questionnaires; Phone Call/Email

Prostate Cancer, or Metastatic (Spread to Other Areas of the Body Clinical Trial using BKM120

Duke University - Recruiting 18 years or older.
- Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.
BKM120

Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy, Clinical Trial using Intermittent dosing of AZD5363

AstraZeneca - Recruiting 18 years or older.
- A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS).
Intermittent dosing of AZD5363

Prostate Cancer Clinical Trial using TAK-700; Bicalutamide

Southwest Oncology Group - Recruiting 18 years or older.
- A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer.
TAK-700; Bicalutamide

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Prostatic Neoplasms Clinical Trial using Cabozantinib; Docetaxel; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
Cabozantinib; Docetaxel; Prednisone

Prostate Cancer Metastatic Clinical Trial using CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Sanofi - Recruiting 18 years or older.
- Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy.
CABAZITAXEL (XRP6258); DOCETAXEL (XRP6976); prednisone

Prostate Cancer, Metastatic Prostate Cancer, or Castration-resist Clinical Trial

Astellas Pharma Inc - Recruiting N/A or older.
- A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis.

Prostatic Neoplams, Prostate Cancer, Neoplasm, Prostate, or Neopl Clinical Trial using AMG 386; Abiraterone; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer.
AMG 386; Abiraterone; Prednisone

Castrate Resistent Prostate Cancer Clinical Trial using BPX-201 vaccine plus AP1903

Bellicum Pharmaceuticals - Recruiting 18 years or older.
- A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC).
BPX-201 vaccine plus AP1903

Metastatic Castration-resistant Prostate Cancer, or Metastatic Br Clinical Trial using Abiraterone acetate

Janssen Research & Development, LLC - Recruiting N/A or older.
- A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Abiraterone acetate

Prostate Cancer Metastatic Clinical Trial using PROSTVAC-V; PROSTVAC-F; GM-CSF; GM-CSF Placebo; Placebo

Bavarian Nordic, Inc. - Recruiting 18 years or older.
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
PROSTVAC-V; PROSTVAC-F; GM-CSF; GM-CSF Placebo; Placebo

Prostate Cancer Clinical Trial using PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer.
PROSTVAC-F/TRICOM; PROSTVAC-V/TRICOM; Enzalutamide (Xtandi)

Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, o Clinical Trial using OGX-427; Abiraterone Acetate; Prednisone

Hoosier Oncology Group - Recruiting 18 years or older.
- The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159.
OGX-427; Abiraterone Acetate; Prednisone

Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Clinical Trial using sipuleucel-T

Dendreon - Recruiting 18 years or older.
- An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer.
sipuleucel-T

Prostate Cancer Clinical Trial using DSTP3086S

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer.
DSTP3086S

Prostate Cancer Clinical Trial using PSMA ADC

Progenics Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer.
PSMA ADC

Prostate Neoplasms, or Prostate Cancer Clinical Trial using Cohort 4; Cohort 3; Cohort 2; Cohort 1

Cougar Biotechnology, Inc. - Recruiting 18 years or older.
- A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Cohort 4; Cohort 3; Cohort 2; Cohort 1

Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistan Clinical Trial using sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer.
sipuleucel-T; external beam radiation therapy; laboratory biomarker analysis

Asian Chemo-na‹ve Patients With Metastatic Castrate-resistant Pro Clinical Trial using Tasquinimod; Placebo

Ipsen - Recruiting 20 years or older.
- A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Na‹ve Patients With Metastatic Castrate-Resistant Prostate Cancer.
Tasquinimod; Placebo

Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Pro Clinical Trial using laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

University of Southern California - Recruiting 18 years or older.
- A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.
laboratory biomarker analysis; questionnaire administration; doxorubicin-GnRH agonist conjugate AEZS-108

Metastatic Prostate Cancer Clinical Trial using cabacitaxel

Tampere University Hospital - Recruiting 18 years or older.
- Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen.
cabacitaxel

Prostate Cancer Clinical Trial using Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer.
Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone

Prostate Cancer Clinical Trial using CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Sanofi - Recruiting 18 years or older.
- A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context..
CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Metastatic Castration-resistant Prostate Cancer Clinical Trial using Taxotere; Jevtana

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer.
Taxotere; Jevtana

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Prostate Cancer Clinical Trial using Orteronel; Bicalutamide

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration..
Orteronel; Bicalutamide

Prostate Cancer Clinical Trial using PET/CT; PET/MRI

New York University School of Medicine - Recruiting 18 years or older.
- Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients.
PET/CT; PET/MRI

Metastatic Prostate Cancer Clinical Trial using sipuleucel-T; enzalutamide

Dendreon - Recruiting 18 years or older.
- A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer.
sipuleucel-T; enzalutamide

Metastatic Castration Sensitive Prostate Cancer Clinical Trial using Degarelix; Ipilimumab; Radical Prostatectomy

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study Combining Ipilimumab and Degarelix With Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer.
Degarelix; Ipilimumab; Radical Prostatectomy

Prostate Cancer Clinical Trial using Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Medivation, Inc. - Recruiting 18 years or older.
- A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Na‹ve Metastatic Castration-Resistant Prostate Cancer.
Enzalutamide; Abiraterone; Placebo for Enzalutamide; Prednisone

Prostate Cancer Clinical Trial using Flutamide; Sargramostim; recombinant fowlpox-prostate apecific antigen vaccine; recombinant vaccinia prostate specific antigen vaccine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer.
Flutamide; Sargramostim; recombinant fowlpox-prostate apecific antigen vaccine; recombinant vaccinia prostate specific antigen vaccine

Prostate Cancer Metastatic Clinical Trial using Cabozantinib

University of Michigan Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Cabozantinib (XL184) in Patients With Castrate-Resistant Prostate Cancer Metastatic to Bone.
Cabozantinib

Prostate Cancer, Castration Resistant Prostate Cancer, or Prostat Clinical Trial using cabozantinib; abiraterone; prednisone

Exelixis - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Na‹ve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer.
cabozantinib; abiraterone; prednisone

Prostate Neoplasms Clinical Trial using Abiraterone acetate; Prednisone; ADT (androgen deprivation therapy); Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC).
Abiraterone acetate; Prednisone; ADT (androgen deprivation therapy); Placebo

Prostate Cancer Clinical Trial using Cabozantinib; Androgen Ablation Therapy

M.D. Anderson Cancer Center - Recruiting N/A or older.
- An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer.
Cabozantinib; Androgen Ablation Therapy

Prostate Cancer Clinical Trial using 3-dimensional conformal radiation therapy (3D-CRT); intensity-modulated radiation therapy (IMRT); samarium Sm 153 lexidronam pentasodium

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy.
3-dimensional conformal radiation therapy (3D-CRT); intensity-modulated radiation therapy (IMRT); samarium Sm 153 lexidronam pentasodium

Metastatic Breast Cancer, Colorectal Cancer, or Prostate Cancer Clinical Trial using Foxy-5

WntResearch AB - Recruiting 18 years or older.
- Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colorectal or Prostate Cancer.
Foxy-5

Metastatic Castration- Resistant Prostate Cancer (mCRCP) Clinical Trial using Enzalutamide

Astellas Pharma Inc - Recruiting N/A or older.
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure.
Enzalutamide

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma.
gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

Metastatic Castration Resistant Prostate Cancer (CRPC) Clinical Trial using Hamsa-1T TL-118

Tiltan Pharma Ltd. - Recruiting 18 years or older.
- A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1T in Metastatic Castration Resistant Prostate Cancer (CRPC).
Hamsa-1T TL-118

Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporo Clinical Trial using Denosumab; Placebo

Amgen - Recruiting 30 years or older.
- A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy.
Denosumab; Placebo

Prostate Cancer Clinical Trial using GTx-758 125 mg; GTx-758 250 mg

GTx - Recruiting 18 years or older.
- Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy.
GTx-758 125 mg; GTx-758 250 mg

Prostate Cancer, or Sexual Dysfunction Clinical Trial using laboratory biomarker analysis; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- HIFU Lesion Control in Patients With Non-metastatic Progressive Prostate Cancer.
laboratory biomarker analysis; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

Prostate Cancer Clinical Trial using gonadotrophin releasing hormone; cyproterone acetate; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 79 years.
- Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer.
gonadotrophin releasing hormone; cyproterone acetate; quality-of-life assessment

Prostate Cancer Clinical Trial using pharmacological study; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A or older.
- An Evaluation of Lesion Control Using Focal Ablation With High Intensity Focused Ultrasound in the Treatment of Non-Metastatic Progressive Prostate Cancer.
pharmacological study; questionnaire administration; assessment of therapy complications; high-intensity focused ultrasound ablation; quality-of-life assessment

Prostate Cancer Clinical Trial using CyberKnife Boost

Boston Medical Center - Recruiting 18 years or older.
- Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer.
CyberKnife Boost

Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Clinical Trial using assessment of therapy complications

Southwest Oncology Group - Recruiting N/A or older.
- S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment.
assessment of therapy complications

Melanoma, Castrate Resistant Prostate Cancer, or Renal Cancer Clinical Trial using Naltrexone

Brown University - Recruiting 18 years or older.
- Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project.
Naltrexone

Metastatic Castration Resistant Prostate Cancer Patients Clinical Trial using metastasis biopsy

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program.
metastasis biopsy

Prostate Cancer Clinical Trial using Pantoprazole

University Health Network, Toronto - Recruiting 18 years or older.
- Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA).
Pantoprazole

Prostate Cancer Clinical Trial using docetaxel; sorafenib tosylate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer.
docetaxel; sorafenib tosylate

Metastatic Prostate Cancer Clinical Trial using 177Lu-CYT-500

Cytogen Corporation - Recruiting 18 years or older.
- A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer.
177Lu-CYT-500